Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer

The authors reported 12-year outcomes of the C9741 trial overall, and by the sensitivity to endocrine therapy test index, a biomarker measuring endocrine transcriptional activity, to identify patients most likely to benefit from dose-dense chemotherapy.